BioSpace News Archive

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced FDA clearance to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody (mAb), ADG126, in combination with the anti-PD-1 antibody pembrolizumab.

Partnership enables Hibiscus BioTechnology Studio Companies access to Innoforce’s advanced therapies drug development capabilities.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the fourth quarter and year ended December 31, 2021 and provides a corporate update.

Enspectra Health announced today that it has been awarded a second tranche of funding in the amount of $1.2 million.

2seventy bio, Inc announced today that it has agreed to sell approximately 13,934,427 shares of its common stock to a select group of institutional and accredited investors in a private placement.

Biogen announced new data showing that after nearly two and a half years of treatment (128 weeks) with ADUHELM.

Alnylam Pharmaceuticals, Inc. today published its 2021 Corporate Responsibility Report.

Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, has announced a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera’s SRGTM rat (OncoRat®).

Sight Sciences, Inc., an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022.

BetterLife Pharma Inc. is pleased to announce it has obtained the first set of positive in vivo pharmacokinetic data confirming the bioavailability of its lead compound BETR-001 in the brain and plasma of treated mice.